Well....I did it. 10 hours later, I managed to meet with Dr. Cortes and 5 'fellows' who sat in. He did tell me that if I had come to him first - or within the first month of diagnosis, he would have put me on Tasigna right away - not Gleevec. He said Gleevec was fine - and still is fine, but Tasigna is showing dramatic, quick results. He knew about Tasigna results long before ASCO. What took patients a year to get to, he is seeing in less than 3 months. He told me that since I was started on Gleevec with minimal (or no) side affects, he wants to let it go for one more month which will take me to the 3 month mark. And then do a BMB, and full molecular work-up to see where I am. If I am responding more slowly than he would like to see, he will switch me. If I am responding quickly (30% of Gleevec patients according to him respond quickly) he would leave me on Gleevec.
He said there are a lot of trials going on to further enhance treatment for those who don't respond. He said the key is quick response - zero detectable Ph+ chromosome - which experience informs him leads to a very good long term outcome (no recurrence). He also said there are lots of cases where low levels persist and lead to very good outcomes, but that those that get to zero within a year have the best outcome. This is why he was positive on Tasigna - get the Leukemia cell burden down quickly. He said Sprycell gives a similar result. He said he would consider me for "cure" trials that are beginning only after the Leukemia cell burden is brought under molecular control. After that, he said we can look into so-called 'cure' trials.
One final thing - he did say he would switch a patient who is long term on Tasigna (more than a year) and at PCR-U to Gleevec for maintenance because of cost. Once Gleevec goes off patent protection it will be a battle with insurance companies to use anything else. That was a side note.
I will meet with my primary Onc and let him know Dr. Cortes' thoughts. In one month I will have a big decision to make.
Dr. Cortes has good patient rapport. He listens, explains and is flexible.











